Skip to main content
Journal cover image

Effects of Elexacaftor/Tezacaftor/Ivacaftor on the Sinonasal Airspace in Cystic Fibrosis.

Publication ,  Journal Article
Kim, MH; Luzum, NA; Kimple, AJ; Zemke, AC; Frank-Ito, D
Published in: Laryngoscope
September 25, 2025

OBJECTIVES: People with Cystic Fibrosis (CF) experience significant sinonasal airway opacification, leading to chronic airway-related conditions. The triple combination therapy Elexacaftor/Tezacaftor/Ivacaftor (ETI) has emerged as a therapeutic option for CF. This study uses volumetric quantification technique to evaluate changes in CF sinonasal airway patency pre-ETI and post-ETI. METHODS: Anatomically accurate person-specific three-dimensional sinonasal airspaces were reconstructed from radiographical images of 19 people (12 male, 7 female) with CF, pre-ETI and post-ETI. Sinonasal airspace surface area, volume, and surface-area-to-volume ratio were calculated pre-ETI and post-ETI. Pre-ETI and post-ETI sinonasal airspace changes in these computed parameters were corrected with changes in both Lund-Mackay and SNOT-22 scores. RESULTS: Median (IQR) surface area and volume increased significantly from pre-ETI (Surface Area: 251.97 cm2 (43.71); Volume: 44.86 cm3 (20.72)) to post-ETI (Surface Area: 295.77 cm2 (31.34); Volume: 61.03 cm3 (14.21)), with respective p < 0.01 per computed parameter. Furthermore, median surface-area-to-volume ratio (IQR) was significantly different; pre-ETI: 0.053 cm-1 (0.007); post-ETI: 0.052 cm-1 (0.013); p = 0.04. Pre-ETI to post-ETI improvement changes in surface area and volume significantly correlated with corresponding changes in Lund-Mackay scores (Surface Area: R = -0.78, p < 0.01; Volume: R = -0.68, p < 0.01), but correlated weakly with corresponding changes in patient-reported SNOT-22 scores (Surface Area: R = -0.13, p = 0.62; Volume: R = -0.06, p = 0.82). CONCLUSION: People with CF treated with ETI exhibited a significant increase in sinonasal airway patency, as evidenced by volumetric quantification analysis of surface area and volume differences. These increases in both parameters showed strong significant correlations with Lund-Mackay scores; however, no such correlations were observed with SNOT-22 scores.

Duke Scholars

Published In

Laryngoscope

DOI

EISSN

1531-4995

Publication Date

September 25, 2025

Location

United States

Related Subject Headings

  • Otorhinolaryngology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kim, M. H., Luzum, N. A., Kimple, A. J., Zemke, A. C., & Frank-Ito, D. (2025). Effects of Elexacaftor/Tezacaftor/Ivacaftor on the Sinonasal Airspace in Cystic Fibrosis. Laryngoscope. https://doi.org/10.1002/lary.70156
Kim, Michelle H., Nathan A. Luzum, Adam J. Kimple, Anna C. Zemke, and Dennis Frank-Ito. “Effects of Elexacaftor/Tezacaftor/Ivacaftor on the Sinonasal Airspace in Cystic Fibrosis.Laryngoscope, September 25, 2025. https://doi.org/10.1002/lary.70156.
Kim MH, Luzum NA, Kimple AJ, Zemke AC, Frank-Ito D. Effects of Elexacaftor/Tezacaftor/Ivacaftor on the Sinonasal Airspace in Cystic Fibrosis. Laryngoscope. 2025 Sep 25;
Kim, Michelle H., et al. “Effects of Elexacaftor/Tezacaftor/Ivacaftor on the Sinonasal Airspace in Cystic Fibrosis.Laryngoscope, Sept. 2025. Pubmed, doi:10.1002/lary.70156.
Kim MH, Luzum NA, Kimple AJ, Zemke AC, Frank-Ito D. Effects of Elexacaftor/Tezacaftor/Ivacaftor on the Sinonasal Airspace in Cystic Fibrosis. Laryngoscope. 2025 Sep 25;
Journal cover image

Published In

Laryngoscope

DOI

EISSN

1531-4995

Publication Date

September 25, 2025

Location

United States

Related Subject Headings

  • Otorhinolaryngology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences